1. Discuss the underlying mechanisms of multiple sclerosis severity in patients with HIV;
2. Select appropriate therapies for both benign and fulminant forms of MS in patients with HIV; and
3. Defi ne the risks of PML and other opportunistic infections in association with specific MS therapies in patients with well-controlled HIV, with and without the history of AIDS


Session date: 
05/31/2018 - 3:00pm to 4:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Elena Grebenciucova MD